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Purpose: Despite indubitable evidence for the cardiovascular benefits of statins, there have
been concerns that statin discontinuation may cause negative effects known as “statin with-
drawal syndrome.” This study aimed to assess the benefit and the withdrawal effect of statins
after percutaneous coronary intervention (PCI).
Patients and Methods: We conducted a retrospective cohort study on 5218 patients who
underwent PCI between 2002 and 2013 using the nationwide health insurance claim data in
Korea. Based on the prescription data, the use of statins during follow-up was classified into
three risk periods: “statin period” (period with statin cover), “statin withdrawal period”
(withdrawal of statin within 30 days), and “no statin period” (no exposure to statin for longer
than 30 days). The primary outcome was the composite outcome of myocardial infarction,
coronary revascularization, stroke, and all-cause death. We performed multivariate Cox pro-
portional regression analyses which treated the use of statins as a time-dependent variable.
Results: During the follow-up period of 3.54 ± 2.91 years (mean ± standard deviation), 1515
(29.0%) patients sustained a primary outcome. Compared with the “no statin period,” the
“statin period” was associated with lower risk of the primary outcome (adjusted hazard ratio
[HR] 0.72, 95% confidence interval [CI, 0.63–0.81]). While the “statin withdrawal period”
posed a significantly increased risk (adjusted HR 1.87, 95% CI [1.52–2.29]). With respect to
the intensity of statins associated with withdrawal, dose-dependent increased risk was
observed for withdrawal of low-, moderate-, and high-intensity statins; adjusted HR [95%
CI] were 1.45 [0.74–2.86], 1.86 [1.49–2.32], and 2.61 [1.41–4.81], respectively.
Conclusion: After PCI, there was an increased cardiovascular risk during the statin with-
drawal period, especially with the use of high-intensity statins. To maximize the beneficial
effect and to avoid the withdrawal effect of statins, high-risk patients need to adhere to taking
statins without discontinuation.
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Introduction
Coronary artery disease (CAD) is the leading cause of morbidity and mortality world-
wide. Statins (3-hydroxy-3-methylglutaryl-CoA reductase inhibitor) are a class of lipid-
lowering agents, which have been established to be effective in reducing cardiovascular
risk.1–3 Current guidelines strongly recommend lifelong statin therapy for high-risk
patients with established CAD.4,5 Despite the established cardiovascular benefits, statin
use is dynamic or intermittent in clinical practice, and suboptimal statin use is frequent.6–8
There is cumulative evidence that discontinuation and non-adherence to the use of statins
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are strongly associatedwith poor cardiovascular prognosis.9–11
However, knowledge of statin use is still limited throughout the
long-term follow-up period in patients with CAD.
Furthermore, sudden discontinuation of statins may cause
additional adverse effects (statin rebound or withdrawal
syndrome).12–14 To evaluate the benefit and the withdrawal
effect of statins in a long-term follow-up period, we conducted
a retrospective cohort study on patients who underwent percu-
taneous coronary intervention (PCI) using the nationwide
health insurance claim data.
Materials and Methods
Data Source
In this study, we used the data from the National Health
Insurance Service-National Sample Cohort (NHIS-NSC)
in Korea.15 South Korea has universal health insurance
coverage by the NHIS under their national plans. The
NHIS-NSC included 1,025,340 individuals selected in
2002 (2.2% of the total eligible Korean population) by
stratified random sampling according to sex, age, and
household income. The NHIS-NSC contains information
on all health claim data between 2002 and 2013 including
hospital visits, medical procedures, drug prescriptions,
diagnoses, and mortality (cause and date of death). The
diagnosis at each hospital visit was recorded according to
the International Classification of Diseases, 10th revision
(ICD-10).
Study Design
This was a retrospective cohort study based on the NHIS-
NSC. We included subjects who were aged ≥20 years and
who underwent PCI (angioplasty with or without stent; they
had health claim codes of “M6561”, “M6562”, “M6563”,
“M6564”, “M6551”, and “M6552”) in 2002–2013. To mini-
mize confounding bias by cancer, we excluded patients who
had a diagnosis code of malignant neoplasms (C00–C97)
during the study period. Index date for each patient was
defined as the admission date for PCI. The primary outcome
was a composite of myocardial infarction (MI), coronary
revascularization, stroke (ischemic and hemorrhagic), and
all-cause mortality, whichever occurred first after the index
date. MI was defined as hospitalization (admission or emer-
gency department visit) with a primary diagnosis of I21.
Coronary revascularization was determined by health claim
codes of PCI (“M6561,” “M6562,” “M6563,” “M6564,”
“M6551,” “M6552”) and coronary artery bypass graft
(“OA631*–OA639*”, “OB631*–OB639*”, “OA641*”,
“OA642*”, “OA647*”, “O0161*–O0171*”, “O1641*–
O1647*”.16 If a patient admitted with MI and received cor-
onary revascularization during the hospitalization period, the
case was classified as MI. Stroke was diagnosed in patients
hospitalized with a primary diagnosis of I60–63 (ischemic
stroke, I63; hemorrhagic stroke, I60–62) and who underwent
brain CTor MRI during the hospital visit. In previous valida-
tion studies with the NHIS, the diagnostic accuracy of I21 for
MI was reported as 73–93%, and I60–I63 for stroke as over
80%.17–20 Several research articles have been published
based on the NHIS health claim data on MI and stroke.21–23
Unless the patient was disqualified from the NHIS because of
death or emigration, all included patients were followed until
December 2013 or the date of the primary outcome. As
a very short period of follow-up was inadequate to evaluate
long-term prognosis following the use and the withdrawal of
statins, those followed up for ≤30 days were excluded. All
data in the NHIS-NSC were fully anonymized. Therefore,
this study was approved, and informed consent was waived,
by the Institutional Review Board of Bundang CHAMedical
Center (CHAMC 2017-03-021).
Prescription Data Including Statin
All prescription data of included patients are available in
the NHIS-NSC. According to the prescription data of
statins, statin treatment during follow-up was classified
into three risk periods: “statin period” (days covered by
statins), “statin withdrawal period” (within 30 days from
the end of the most recent statin exposure), and “no statin
period” (no statin exposure for more than 30 days).
Figure 1 illustrates examples of the risk periods according
to the respective statin treatment regimes. In the “statin
withdrawal period,” the intensity of the last used statins
(low, intermediate, or high) was determined by the daily
dose and type (atorvastatin, fluvastatin, rosuvastatin, pita-
vastatin, pravastatin, simvastatin, and lovastatin) accord-
ing to the classification in the 2013 American Heart
Association guideline on the treatment of high blood
cholesterol.4 As a covariate, we also collected data on
the use of aspirin and adenosine diphosphate (ADP)
receptor antagonist (clopidogrel, ticlopidine, ticagrelor
and prasugrel). The use of statins and antiplatelets during
follow-up was treated as a time-dependent variable for
analyses.
Other Covariates
We identified the data on sex, age (classified into five-year
groups in the NHIS-NSC), and household income as
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a marker of socioeconomic status in the year in which PCI
was undertaken. Household income obtained from the
NHIS-NSC was subdivided into tertile groups (low, mid-
dle, and high) for analytical convenience. Hypertension
(I10–15), diabetes mellitus (E08–11, E13–14), and atrial
fibrillation (I48) were defined based on the presence of the
diagnostic codes (ICD-10) in the NHIS-NSC before or at
the time of discharge after PCI. Hypertension and diabetes
mellitus were recognized as relevant only if the subjects
received antihypertensive (calcium-channel blockers,
angiotensin-converting enzyme inhibitors, angiotensin-
receptor blockers, diuretics, beta-blockers, alpha-
blockers, or vasodilators) or antidiabetic (sulfonylureas,
biguanides, alpha-glucosidase inhibitors, thiazolidine-
diones, meglitinides, glucagon-like peptide-1 receptor ago-
nists, dipeptidyl peptidase-4 inhibitors, or insulin) agents
in combination with the respective diagnostic codes.24
A history of MI was determined when a patient was
admitted with a diagnosis of “I21” before or upon the
decision to perform PCI.
Statistical Analysis
We computed the hazard ratio (HR) and 95% confidence
interval (CI) for the primary outcome using time-
dependent Cox proportional hazard regression analyses.
The assumption of proportional hazards in the Cox models
was tested by evaluating scaled Schoenfeld residuals,
which were found to be satisfactory. Adjustments were
performed for sex; age (as continuous variables); level of
household income; presence of hypertension, diabetes
mellitus, atrial fibrillation, and MI (as time-independent
variables); and use of antiplatelets, and statins during
follow-up (as time-dependent variables). As secondary
outcome analysis, we constructed individual Cox regres-
sion models for each clinical outcome (MI, coronary
revascularization, stroke, and all-cause mortality). The
data manipulation and statistical analyses were performed
with PostgreSQL version 10.1 (The PostgreSQL Global
Development Group; https://www.postgresql.org/) and
R software version 3.4.1 (The R Foundation for
Statistical Computing, Vienna, Austria; http://www.
R-project.org/). A two-sided P-value of <0.05 was consid-
ered statistically significant.
Data Availability
Requests for access to the NHIS data can be made through the
homepage of National Health Insurance Sharing Service
[http://nhiss.nhis.or.kr/bd/ab/bdaba021eng.do]. To gain access
to the data, a completed application form, a research proposal,
and the applicant’s approval document from the institutional
review board should be submitted to and reviewed by the
inquiry committee of research support in the NHIS. The
NHIS-NSC data were fully anonymized and did not contain
any information that allowed patient identification.
Results
In the NHIS-NSC, there were 7682 adult patients (age ≥20
years) who underwent PCI between 2002 and 2013. After
91-1201-90 121-180 181-225 256-
statin period withdrawal period (withdrawal within 30 days) no statin period (no use > 30 days)
at Day 1
Atorvastatin 40 mg x 90 days
at Day 181





Rosuvastatin 10 mg x 90 days
at Day 111
Rosuvastatin 10 mg x 100 days
211-240
Case 2
Index date (admission for PCI, 1 day)
Statin prescription
Index date (admission for PCI, 1 day)
Statin prescription
Figure 1 Examples of the definition of risk periods according to statin treatment.
Abbreviation: PCI, percutaneous coronary intervention.
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excluding 2464 patients who were followed up for ≤30
days or who had diagnosis of malignant neoplasms, we
finally included 5218 patients. Among the 5218 included
patients, 65.2% were male, and the median age was 60–64
years (Table 1). The total study follow-up period of study
patients was 18,049 person-years. Of them, the proportion
of days-covered by any statins were 71.3% (12,866 per-
son-years). In terms of the percentage of individual statins
used, atorvastatin was the highest (44.9%), and rosuvasta-
tin (23.0%) and simvastatin (16.1%) were second and
third. During the follow–up period of 3.54 ± 2.91 years
(mean ± standard deviation), there were 1515 patients
(29.0%) who suffered primary outcome events (358 with
MI, 670 with coronary revascularization, 181 with stroke,
and 303 with all-cause mortality; considering only the
earliest outcome for each patient).
In a time-dependent Cox regression analysis (Table 2), the
“statin period” was significantly associated with lower risk of
the primary outcome after PCI compared with the “no statin
period” (adjusted HR [95% CI], 0.72 [0.63–0.81], p < 0.001).
While the “statin withdrawal period” resulted in a significantly
increased risk of the primary outcome (adjusted HR [95%CI],
1.87 [1.50–2.29], p < 0.001). Further analysis with respect to
the intensity of the statin used just before withdrawal revealed
Table 1 Clinical Characteristics of Patients Who Received
Percutaneous Coronary Intervention
Variable [All] N = 5218
Sex, male 3402 (65.2)
Age 60–64 [50–54; 70–74]
Hypertension 4511 (86.5)
Diabetes mellitus 1742 (33.4)
Atrial fibrillation 436 (8.4)









Note: Data are number (%) or median [interquartile range].
Table 2 Result of Cox Regression Analyses for Primary Outcome After Percutaneous Coronary Intervention
Variable Univariate Multivariate
Unadjusted HR [95% CI] p-value Adjusted HR [95% CI] p-value
Time-fixed variables
Sex, male 0.98 [0.88–1.08] 0.646 1.06 [0.95–1.19] 0.292
Age, per 5 years 1.07 [1.05–1.10] < 0.001 1.07 [1.04–1.10] < 0.001
Hypertension 1.09 [0.93–1.27] 0.302 1.02 [0.87–1.20] 0.082
Diabetes mellitus 1.34 [1.20–1.48] < 0.001 1.33 [1.19–1.47] < 0.001
Atrial fibrillation 1.27 [1.08–1.50] < 0.001 1.16 [0.98–1.37] 0.090
Myocardial infarction 1.42 [1.28–1.57] < 0.001 1.42 [1.29–1.58] < 0.001
Household Income
Low 1 (Ref) – 1 (Ref) –
Middle 0.99 [0.87–1.12] 0.863 1.03 [0.91–1.17] 0.637
High 1.05 [0.92–1.19] 0.456 1.08 [0.95–1.23] 0.243
Time-dependent Variables
Antiplatelets
No aspirin, no ADPRB 1 (Ref) – 1 (Ref) –
Aspirin only 0.49 [0.42–0.57] < 0.001 0.71 [0.59–0.85] < 0.001
ADPRB only 0.58 [0.46–0.72] < 0.001 0.82 [0.64–1.05] 0.120
Aspirin plus ADPRB 0.69 [0.60–0.80] < 0.001 1.03 [0.86–1.23] 0.730
Statins
No statin 1 (Ref) – 1 (Ref) –
Statin use 0.69 [0.62–0.78] < 0.001 0.72 [0.63–0.81] < 0.001
Withdrawal 1.90 [1.56–2.32] < 0.001 1.87 [1.52–2.29] < 0.001
Note: Data are derived from multivariate time-dependent Cox proportional hazard regression model.
Abbreviations: ADPRB, adenosine diphosphate receptor blocker (clopidogrel, prasugrel, ticlopidine, ticagrelor); CI, confidence interval; HR, hazard ratio.
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an inverse dose–response relationship between risk of the
primary outcome and the intensity of statin. Adjusted HR
[95% CI] for withdrawal of “low-,” “moderate-,” and “high-
intensity” statin compared to that in the “no statin period”were
1.45 [0.74–2.86], 1.86 [1.49–2.32], and 2.61 [1.41–4.81],
respectively (Figure 2). This finding suggested a greater
rebound phenomenon with discontinuation of a high-
intensity statin compared to the rebound observed with dis-
continuation of a low-intensity statin. In the secondary out-
come analysis for individual outcomes, statin withdrawal was
significantly associated with increased risk for MI, coronary
revascularization, and all-cause death (Table 3).
Discussion
The current study evaluated the beneficial effect and the
withdrawal effect of statins in a long-term period after PCI
based on real-world data. The current guidelines strongly
recommend that high-intensity statin therapy should be
continued before and after PCI to reduce the development
of cardiovascular adverse events.25,26 Statins are generally
well tolerated, but as many as 20–30% of patients report
adverse events, and discontinuation of statin is very com-
mon in the clinical setting.6,12,27 About half of patients
starting statin therapy discontinue the statin within the
first year, and adherence to the statin decreases with
time.28 Despite the emphasis on high-intensity statin use
in the guidelines, adherence to high-intensity statins was
relatively lower compared with adherence to low- to mod-
erate-intensity statins, and there were more frequent
adverse events.23,29
Suboptimal use and discontinuation of statins have been
important clinical issues.10,30,31 After myocardial infarction,
early discontinuation of statins was a significant risk factor
for worse clinical outcomes.32,33 In patients who had under-
gone major vascular surgery, statin discontinuation during
the postoperative period was associated with a higher inci-
dence of myocardial ischemia, nonfatal myocardial infarc-
tion, and cardiovascular death.9 Previous studies have
focused mainly on the risk of statin discontinuation in the
early phase after vascular events. Our longitudinal study
evaluated the prognosis according to the use and discontinua-
tion of statin during a long-term period. After PCI, patients
who received statin treatment were at a significantly lower
risk of the primary outcome, which means that statin therapy
should be continued to maintain the protective effects on the
cardiovascular system.
In this study, statin withdrawal led to an increased risk in
excess of that of no statin use. More interestingly, the degree
of withdrawal effect was correlated with the intensity of the
statin last taken. These findings suggest the presence of
a rebound phenomenon in the early period of statin with-
drawal, known as “statin withdrawal syndrome.” To max-
imize the cardiovascular benefits of statin therapy and to
avoid the detrimental effect of statin withdrawal, there is
Risk period
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Figure 2 Risk for primary outcome according to statin treatment. (A) Adjusted HR for “statin use period” and “withdrawal period” compared to the “no statin period”
(Ref). (B) Adjusted HR for statin withdrawal for “low-intensity”, “moderate-intensity”, and “high-intensity” statins compared to the “no statin period” (Ref). Data are
derived from multivariate time-dependent Cox proportional hazard regression analysis adjusted for the variables listed in Table 2
Abbreviations: CI, confidence interval; HR, hazard ratio.
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a need to develop more practical interventions combining
educational and behavioral components.28,34,35 The
European Atherosclerosis Society Consensus Panel recom-
mends brief discontinuation and re-initiation of statin therapy
in patients with statin intolerance such as statin-attributed
muscle symptoms.36 Based on the results of the present
study, we found that a greater rebound effect occurs in
association with withdrawal from high-intensity statins, and
this is proportional to the statin intensity. Therefore, when
statin intolerance develops (except in patients with serious
side effects), it might be reasonable to down-titrate the dose
initially rather than to abruptly stop the drugs or change to
non-statins, especially in those taking high-intensity statins.
Some mechanisms have been proposed to explain the
rebound phenomenon caused by statin withdrawal: 1)
Induction of vascular dysfunction: The Rho family of gua-
nosine triphosphates (GTP) is a family of small signaling
G proteins which modulate the levels of nitric oxide,
production of reactive oxygen species, and levels of angio-
tensin II-AT1 receptors, endothelin-I, adhesion molecules,
and inflammatory cytokines.12 Statins can block isopre-
noid-dependent Rho membrane translocation and GTP-
binding activity, which leads to upregulation of endothelial
nitric oxide synthase expression and accumulation of non-
isoprenylated Rho protein in the endothelial cytosol, indu-
cing a vascular protective effect.37 Withdrawing statins can
restore the availability of isoprenoids and result in
a rebound activation of Rho and downregulation of
endothelial nitric oxide production. Acute statin withdrawal
increases angiotensin II receptor type 1 activity in smooth
muscle cells and exacerbates vascular dysfunction.38 2)
Rebound of inflammatory response: Statin withdrawal
could induce a rebound phenomenon of the inflammatory
response by increasing expression of inflammatory markers
like C-reactive protein and interleukin-6.39 In an experi-
mental study on human and rat vascular smooth muscle
cells, statin withdrawal increased levels of proatherogenic
substances, such as free radicals, monocyte chemoattractant
protein 1, and tissue factor gene expression.40 3) Decreased
angiogenesis: Statin discontinuation was purported to
reduce angiogenesis, which could delay myocardial recov-
ery after acute coronary syndrome.41
We should acknowledge the possible limitations of this
study. This study had a retrospective cohort design; there-
fore, it might have confounding effects. Although there are
previous validation studies for the outcome measures that
used the NHIS database, non-hospitalized outcomes could
not be captured with the limitations of the health claim
database. We determined statin treatment by accessing the
prescription data on the NHIS database. Actual statin use
might have been different from the prescription data.
Further large clinical and experimental studies are needed
to evaluate the effect of “statin withdrawal” on cardiovas-
cular prognosis and the underlying mechanisms.
Conclusion
After PCI, the use of statins showed a significant beneficial
effect in the long-term period. Withdrawal of statins resulted
in increased risk of cardiovascular events. Clinicians should
take comprehensive measures to ensure that continued use
of statins is maintained in all patients after PCI.
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Table 3 Secondary Outcome Analysis for Individual Outcome
Event of Interest Myocardial Infarction Coronary Revascularization Stroke All-Cause Death
Risk period
No statin 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref)
Statin use 0.84 [0.64–1.11] 0.79 [0.66–0.94] 0.73 [0.33–1.61] 0.44 [0.34–0.58]
Withdrawal 2.11 [1.39–3.20] 2.43 [1.81–3.26] 0.78 [0.55–1.12] 1.49 [1.02–2.18]
Notes: Data are adjusted hazard ratio [95% confidence interval] derived from multivariate time-dependent Cox proportional hazard regression models for
individual outcomes. Adjustments were performed for same variables listed in Table 2.
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